Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate in refractory partial epilepsy
NCT00236691Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 1988
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of topiramate in partial epilepsy (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Percent reduction in the average monthly seizure rate at 18 weeks. Started Jul 1988; status: completed.
02
Drugs
topiramate
03
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT00236691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236691.